title: University of California at San Francisco criteria can be applied to living donor liver transplantation for hepatocellular carcinoma: single-center preliminary results in 27 patients.
abstract: BACKGROUND
  Living donor liver transplantation (LDLT) can provide life-saving therapy for many patients with hepatocellular carcinoma (HCC), who otherwise would succumb due to tumor progression. However, donor risk must be balanced against potential recipient benefit.
  
  
  METHODS
  From January 2002 to December 2006, a total of 27 LDLT were performed for HCC patients in our center, including 25 right lobe grafts, and 2 dual grafts. Twenty-four (88.89%) met the University of California at San Francisco (UCSF) criteria, whereas 3 (11.11%) did not.
  
  
  RESULTS
  Of our 29 donors, the overall complication rate was 17.24%. Two (6.90%) experienced major complications including intra-abdominal bleeding and portal vein thrombosis in 1, respectively; 3 (10.34%) experienced minor complications: wound steatosis, pleural effusion, and transient chyle leakage in 1, respectively. We did not observe any donor mortality; all donors fully recovered and returned to their previous occupations. No recipient developed small-for-size syndrome. The overall HCC patient survival rates at 1- and 3-years were 84.01% and 71.40%, respectively, similar to those of patients undergoing LDLT for various nonmalignant diseases during the same period (P > .05).
  
  
  CONCLUSIONS
  Although further study is needed to fully assess the risks and benefits of LDLT for both HCC patients and donors, our preliminary results suggested that LDLT offered an acceptable chance and duration of survival for HCC patients. It was not only a relatively safe procedure provided that every effort was taken to minimize donor morbidities, but also beneficial for HCC recipients.
authors.affiliation: Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
authors.forename: X-Z
authors.initials: XZ
authors.lastname: Jiang
authors.forename: L-N
authors.initials: LN
authors.lastname: Yan
authors.forename: T-F
authors.initials: TF
authors.lastname: Wen
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Zeng
authors.forename: J-C
authors.initials: JC
authors.lastname: Zhao
authors.forename: W-T
authors.initials: WT
authors.lastname: Wang
authors.forename: J-Y
authors.initials: JY
authors.lastname: Yang
authors.forename: M-Q
authors.initials: MQ
authors.lastname: Xu
authors.forename: Z-Y
authors.initials: ZY
authors.lastname: Chen
authors.forename: Y-K
authors.initials: YK
authors.lastname: Ma
authors.forename: F-G
authors.initials: FG
authors.lastname: Li
authors.forename: G
authors.initials: G
authors.lastname: Gong
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D019520:Living Donors / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D012495:San Francisco; D016019:Survival Analysis